USP28 and melanoma: In the VanAllen 2015 cohort of melanoma tumors, patients with high USP28 expression responded 10% to anti-CTLA4 therapy, which was significantly lower than the 36.3% response rate observed in low-USP28 expression patients (Figure 8E).